XOMA Royalty Corp

NASDAQ:XOMAUnited States

Royalty purchase agreement asset impairment 23,000 1,575 Gain on the acquisition of Kinnate (19,316) -- Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs -- (75) Common stock contribution to 401(k) 118 123 Amortization of intangible assets -- 673 Depreciation 8 2 Accretion of long-term debt discount and debt issuance costs 996 -- Non-cash lease expense 45 115 Change in fair value of equity securities (624) 121 Change in fair value of available-for-sale debt securities classified as cash equivalents 104 -- Changes in assets and liabilities: Trade and other receivables, net (41) (42) Prepaid expenses and other assets (72) (202) Accounts payable and accrued liabilities (1,348) (554) Operating lease liabilities (185) (120) Unearned revenue recognized under units-of-revenue method (1,828) (1,575) ------- ------- Net cash used in operating activities (10,845) (14,231) ------- ------- Cash flows from investing activities: Net cash acquired in Kinnate acquisition 18,926 -- Payments of consideration under RPAs, AAAs, and CPPAs (37,000) (14,650) Receipts under RPAs, AAAs, and CPPAs 26,263 8,428 Purchase of property and equipment (17) -- Net cash provided by (used in) investing activities 8,172 (6,222) ------- ------- Cash flows from financing activities: Principal payments -- debt (6,902) -- Debt issuance costs and loan fees paid in connection with long-term debt (740) -- Payment of preferred stock dividends (4,104) (4,104) Repurchases of common stock (13) -- Proceeds from exercise of options and other share-based compensation 4,127 208 Taxes paid related to net share settlement of equity awards (2,429) (5) Net cash used in financing activities (10,061) (3,901) ------- ------- Net decrease in cash, cash equivalents, and restricted cash (12,734) (24,354) Cash, cash equivalents, and restricted cash as of the beginning of the period 159,550 57,826 Cash, cash equivalents, and restricted cash as of the end of the period $146,816 $ 33,472 ======= ======= Supplemental Cash Flow Information: Cash paid for interest $ 9,985 $ -- Right-of-use assets obtained in exchange for operating lease liabilities $ -- $ 85 Non-cash investing and financing activities: Estimated initial fair value of the Exarafenib milestone asset in Kinnate acquisition $ 2,922 $ -- Estimated initial fair value of the Exarafenib milestone contingent consideration in Kinnate acquisition $ 2,922 $ -- Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition $ 824 $ -- Relative fair value basis reduction of right-of-use assets in Kinnate acquisition $ (824) $ -- Accrual of contingent consideration under the Affitech CPPA $ 3,000 $ 3,000 Accrual of contingent consideration under the LadRx AAA $ 1,000 -- Estimated fair value of contingent consideration under the LadRx Agreements $ -- $ 1,000 Preferred stock dividend accrual $ 1,368 $ 1,368 Investor contact: Media contact: Juliane Snowden Kathy Vincent XOMA Royalty Corporation KV Consulting & Management +1-646-438-9754 +1-310-403-8951 juliane.snowden@xoma.com kathy@kathyvincent.com

XOMA Royalty Corporation ( XOMA ) is currently at $28.46, down $3.47 or 10.87%

--Would be lowest close since Oct. 21, 2024, when it closed at $28.46

--On pace for largest percent decrease since Jan. 9, 2023, when it fell 18.47%